Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis

Lung Cancer

Volumn 98, Issue , 2016, Pages 106-113

  Laccetti, Andrew L ^a   Pruitt, Sandi L ^a,b   Xuan, Lei ^a   Halm, Ethan A ^a,b   Gerber, David E ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Clinical trial design; Lung cancer; Prior malignancy; Survival

Indexed keywords

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL HISTORY; MEDICARE; MOLECULARLY TARGETED THERAPY; PATIENT HISTORY OF PRIOR CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SECOND CANCER; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL RATE; UROGENITAL TRACT CANCER; VERY ELDERLY; CAUSE OF DEATH; LUNG TUMOR; MORTALITY; PATHOLOGY; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; UNITED STATES;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICARE; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; UNITED STATES;

EID: 84973879724     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.05.029     Document Type: Article

References (35)

1. Gerber D.E., Iyengar P. Chapter 8: locally advanced non-Small cell lung cancer. Oxford American Oncology Library: Lung Cancer 2013, Oxford University Press, New York, NY. A.K. Ganti, D.E. Gerber (Eds.).
2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics. CA: Cancer J. Clin. 2014, 6(41):9-29.
3. Albain K.S., Swann R.S., Rusch V.W., Turrisi A.T., Shepherd F.A., Smith C., Chen Y., Livingston R.B., Feins R.H., Gandara D.R., Fry W.A., Darling G., Johnson D.H., Green M.R., Miller R.C., Ley J., Sause W.T., Cox J.D. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374(9687):379-386.
4. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., Curran W.J. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J. Clin. Oncol. 2005, 23(25):5883-5891.
5. Bradley J.D., Paulus R., Komaki R., Masters G., Blumenschein G., Schild S., Bogart J., Hu C., Forster K., Magliocco A., Kavadi V., Garces Y.I., Narayan S., Iyengar P., Robinson C., Wynn R.B., Koprowski C., Meng J., Beitler J., FGaur R., Curran W., Choy H. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomized, two-by-two factorial phase 3 study. Lancet Oncol. 2015, 16(2):187-199.
6. Hanna N., Neubauer M., Yiannoutsos C., McGarry R., Arseneau J., Ansari R., Reynolds C., Govindan R., Melnyk A., Fisher W., Richards D., Bruetman D., Anderson T., Chowhan N., Nattam S., Mantravadi P., Johnson C., Breen T., White A., Einhorn L. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S Oncology. J. Clin. Oncol. 2008, 26(35):5755-5760.
7. Kelly K., Chansky K., Gaspar L.E., Albain K.S., Jett J., Ung Y.C., Lau D.H., Crowley J.J., Gandara D.R. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol. 2008, 26(15):2450-2456.
8. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358(11):1160-1174.
9. Murthy V.H., Krumholz H.M., Gross C.P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA: J. Am. Med. Assoc. 2004, 291(22):2720-2726.
10. Lara P.N., Higdon R., Lim N., Kwan K., Tanaka M., Lau D.H., Wun T., Welborn J., Meyers F.J., Christensen S., O'Donnell R., Richman C., Scudder S.A., Tuscano J., Gandara D.R., Lam K.S. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J. Clin. Oncol. 2001, 19(6):1728-1733.
11. Denicoff A.M., McCaskill-Stevens W., Grubbs S.S., Bruinooge S.S., Comis R.L., Devine P., Dilts D.M., Duff M.E., Ford J.G., Joffe S., Schapira L., Weinfurt K.P., Michaels M., Raghavan D., Richmond E.S., Zon R., Albrecht T.L., Bookman M.A., Dowlati A., Enos R.A., Fouad M.N., Good M., Hicks W.J., Loehrer P.J., Lyss A.P., Wolff S.N., Wujcik D.M., Meropol N.J. The national cancer institute-american society of clinical oncology cancer trial accrual symposium: summary and recommendations. J. Oncol. Pract. 2013, 9(6):267-276.
12. Fuks A., Weijer C., Freedman B., Shapiro S., Skrutkowska M., Riaz A. A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J. Clin. Epidemiol. 1998, 51(2):69-79.
13. Gerber D.E., Laccetti A.L., Xuan L., Halm E.A., Pruitt S.L. Impact of prior cancer on eligibility for lung cancer clinical trials. J. Natl. Cancer Inst. 2014, 106(11).
14. Aguilo R., Macia F., Porta M., Casamitjana M., Minguella J., Novoa A.M. Multiple independent primary cancers do not adversely affect survival of the lung cancer patient. Eur. J. Cardiothorac. Surg. 2008, 34(5):1075-1080.
15. Duchateau C.S., Stokkel M.P. Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival. Chest 2005, 127(4):1152-1158.
16. Lopez-Encuentra A., Gomez de la Camara A., Rami-Porta R., Duque-Medina J.L., de Nicolas J.L., Sayas J., Bronchogenic P. Carcinoma Cooperative Group of the Spanish Society of, S., Thoracic, Previous tumour as a prognostic factor in stage I non-small cell lung cancer. Thorax 2007, 62(5):386-390.
17. Liu Y.Y., Chen Y.M., Yen S.H., Tsai C.M., Perng R.P. Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis. Lung Cancer 2002, 35(2):189-194.
18. Massard G., Ducrocq X., Beaufigeau M., Elia S., Kessler R., Herve J., Wihlm J. Lung cancer following previous extrapulmonary malignancy. Eur. J. Cardiothorac. Surg. 2000, 18(5):524-528.
19. Laccetti A.L., Pruitt S.L., Xuan L., Halm E.A., Gerber D.E. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J. Natl. Cancer Inst. 2015, 107(4).
20. Warren J.L., Klabunde C.N., Schrag D., Bach P.B., Riley G.F. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med. Care 2002, 40(8 Suppl). IV-3-18.
21. Altekruse S.F., Kosary C.L., Krapcho M., Neyman N., Aminou R., Waldron W., Ruhl J., Howlader N., Tatalovich Z., Cho H., Mariotto A., Eisner M.P., Lewis D.R., Cronin K., Chen H.S., Feuer E.J., Stinchcomb D.G., Edwards B.K.e. SEER Cancer Statistics Review, 1975-2007 2010, National Cancer Institute Bethesda, MD, (based on November 2009 SEER data submission, posted to the SEER web site). http://seer.cancer.gov/csr/1975_2007/,
22. Adamo M.D., Dickie L., Ruhl J. National Cancer Institute SEER Coding and Staging Manual 2015, (accessed 10.07.15). http://seer.cancer.gov/manuals/2015/SPCSM_2015_maindoc.pdf.
23. Coyte A., Morrison D.S., McLoone P. Second primary cancer risk-the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. BMC Cancer 2014, 14:272.
24. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355(24):2542-2550.
25. Ahn D.H., Mehta N., Yorio J.T., Xie Y., Yan J., Gerber D.E. Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer. Clin. Lung Cancer 2013.
26. Warren J.L., Yabroff K.R., Meekins A., Topor M., Lamont E.B., Brown M.L. Evaluation of trends in the cost of initial cancer treatment. J. Natl. Cancer Inst. 2008, 100(12):888-897.
27. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987, 40(5):373-383.
28. National Cancer Institute SEER-Medicare: Calculation of Comorbidity Weights (accessed Accessed on: 18.07.11). http://healthservices.cancer.gov/seermedicare/program/comorbidity.html.
29. Koroukian S.M., Dahman B., Copeland G., Bradley C.J. The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study. Health Serv. Res. 2010, 45(1):265-282.
30. Horn L., Keedy V.L., Campbell N., Garcia G., Hayes A., Spencer B., Carbone D.P., Sandler A., Johnson D.H. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin. Lung Cancer 2013, 14(1):14-18.
31. Levi F., Randimbison L., Rafael B.M., Manuela M.C., Vecchia C.L. Second primary cancers in the vaud and neuchatel cancer registries. Eur. J. Cancer Prev. 2014.
32. de Moor J.S., Mariotto A.B., Parry C., Alfano C.M., Padgett L., Kent E.E., Forsythe L., Scoppa S., Hachey M., Rowland J.H. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care, cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. Am. Soc. Prev. Oncol. 2013, 22(4):561-570.
33. Moyer V.A. Screening for prostate cancer: u.S. preventive services task force recommendation statement. Ann. Intern. Med. 2012, 157(2):120-134.
34. Sankila R., Hakulinen T. Survival of patients with colorectal carcinoma: effect of prior breast cancer. J. Natl. Cancer Inst. 1998, 90(1):63-65.
35. Bunn P.A., Lilenbaum R. Chemotherapy for elderly patients with advanced non-small cell lung cancer. J. Natl. Cancer Inst. 2003, 95(5):341-343.